Bristol Myers Squibb Announces Positive Topline Results From Registrational Phase 2 QUINTESSENTIAL Trial Of The Potential First-In-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...
BMY•Positive topline results from QUINTESSENTIAL trial
Sept. 8 (Reuters) - Bristol-Myers Squibb Company BMY.N:
- Bristol Myers Squibb announces positive topline results from registrational Phase 2 QUINTESSENTIAL trial of the potential first-in-class GPRC5D-directed CAR T cell therapy, arlocabtagene autoleucel ...
- Bristol-Myers Squibb Company - Phase 2 trial met primary endpoint of overall response rate and complete response rate
- Bristol-Myers Squibb Company - Arlo-cel safety profile consistent with other CAR T cell therapies
- Bristol-Myers Squibb Company - Study met key secondary endpoint of complete response rate in quadruple-class exposed RRMM
- Bristol-Myers Squibb Company - Arlo-cel shows significant overall response rate in patients with four or more prior therapies
Source text: ID:nBw8b0Sxha
Further company coverage: BMY.N
